delveinsightme
delveinsightme
Delve Insight
Statistics
We looked inside some of the posts by delveinsightme and here's what we found interesting.
Inside last 20 posts
Time between posts
406455.5
Number of posts by type
Photo
0
Video
0
Audio
0
Text
0
Chat
0
Answer
0
Link
0
Quote
0
Explore Tagged Posts
delveinsightme · 3 days ago
Text
Arteriovenous Fistula Market
Arteriovenous Fistula is an abnormal connection between an artery and a vein. Normally, blood flows from the arteries to the capillaries and into the veins. Nutrients and oxygen in the blood travel from capillaries to tissues in the body. With an arteriovenous fistula, blood flows directly from an artery into a vein, bypassing some capillaries, which leads to diminished blood supply in the tissues below the bypassed capillaries. Causes of arteriovenous fistulas include cardiac catheterization, injuries that pierce the skin, being born with an arteriovenous fistula, genetic conditions (such as Osler-Weber-Rendu disease, also known as hereditary hemorrhagic telangiectasia), and/or surgical creation (AV fistula procedure).
DelveInsight’s “Arteriovenous Fistula Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Arteriovenous Fistula, historical and forecasted epidemiology as well as the Arteriovenous Fistula market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Get a Free Sample Copy of the Report at: https://www.delveinsight.com/sample-request/arteriovenous-fistula-market
Arteriovenous Fistula Market Key Facts
Another     study by Pisoni et al. titled “Vascular access use in Europe and the     United States: Results from the DOPPS” found that AVF was used by 80% of     EUR countries (France, Germany, Italy, Spain, and the United Kingdom) and     24% of US prevalent patients. 
According     to a study conducted by Woodside et al. titled “Arteriovenous Fistula     Maturation in Prevalent Hemodialysis Patients in the United States: A     National Study”, wherein 45,087 new AVFs were placed in 39,820 prevalent     hemodialysis patients. In addition, only 54.7% of AVFs were used within 4     months of placement, with maturation rates varying considerably across     end-stage renal disease (ESRD) networks.
As     per the United States Renal Data System, in 2016, 80% of patients were     using a catheter at hemodialysis (HD) initiation. Out of these,     arteriovenous (AV) fistula use at HD initiation rose from 12-17% over the     period 2005-2016. The percentage of patients using an AV fistula or with a     maturing AV fistula at HD initiation increased from 28.9-33.4% over the     same period.
The dynamics of the Arteriovenous fistula market is anticipated to change in the coming years owing to the positive outcomes of the emerging therapies by major key players. The launch of emerging therapies is expected during the forecast period.
Arteriovenous Fistula Companies:
Vascular     therapies
Bard     Peripheral Vascular 
Intact     Vascular
Alucent     Biomedical
And many others. 
Get a Free Sample Copy of the Report at: https://www.delveinsight.com/sample-request/arteriovenous-fistula-market
Key Benefits of Arteriovenous Fistula Market Report:
Arteriovenous     Fistula market report provides an in-depth analysis of     Arteriovenous Fistula Market Size, Share, Trend, Epidemiology and Market     Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain,     France, and the UK), Japan, and the United States.
The     Arteriovenous Fistula market report will help in developing business     strategies by understanding the Arteriovenous Fistula Market     trends & developments, key players, and future market competition     that will shape and drive the Arteriovenous Fistula market in the upcoming     years.
The     Arteriovenous Fistula market report covers Arteriovenous Fistula     market growth and current treatment practices, emerging     drugs, market share of the individual therapies in 7 MM.
The     report provides a detailed assessment of the Arteriovenous Fistula     patient population, market drivers & barriers, Unmet Needs,     market opportunities, comparative analysis of pipeline products with     detailed clinical profiles, and other factors. 
Arteriovenous Fistula Therapies:
Sirogen
Angioplasty     with balloon impregnated with paclitaxel
Tack     Endovascular System
And many more.
Get a Free Sample Copy of the Report at: https://www.delveinsight.com/sample-request/arteriovenous-fistula-market
Latest Reports By DelveInsight:
·         Alstrom Syndrome Market
·         Anterior Cruciate Ligament Injuries Market
·         Amblyopia Market
·         Asherman’s Syndrome Market
·         Astigmatism Market
·         Autoimmune Hepatitis Market
·         Autosomal Recessive Congenital Ichthyosis Market
·         Beta Thalassemia Market
·         Biliary Stents Market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
0 notes
delveinsightme · 28 days ago
Text
DelveInsight Reports: Contusion Market, Growth Hormone Deficiency Market, Giant Papillary Conjunctivitis Market, Chronic Pruritus Market
Contusion Market
Contusion happens when an injured capillary or blood vessel leaks blood into the surrounding area. Contusions are a type of hematoma, which refers to any collection of blood outside of a blood vessel. While the term contusion might sound serious, it’s just a medical term for the common bruise.
Just like the rest of your body, your bones are made of tissue and blood vessels. Any injury to this tissue can cause one or more blood vessels to leak blood. A hard fall, car accident, or high-impact sports injury can all cause bone contusions.
The symptoms of a bone contusion include:
stiffness or swelling
tenderness
trouble bending or using the     affected area
pain that lasts longer than the     symptoms of a typical bruise would
Soft tissue contusions refer to injuries to your muscle or skin tissue. This is also what most people are referring to when they talk about a basic bruise. Soft tissue contusions are must easier to diagnose than bone contusions because they have distinct characteristics, including:
·         discolored skin that looks red, green, purple, blue, or black
·         a small bump over the area in some cases
·         pain that’s usually worse when pressure is applied to the area
Some of the Contusion Companies are:
·         GSK
·         Novo Nordisk
·         Biogen
·         Novartis
·         And Many Others
View Report: https://www.delveinsight.com/report-store/contusion-market
 Growth Hormone Deficiency Market
Growth hormone deficiency is a condition where the pituitary gland is unable to make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A third category has no known or diagnosable cause (idiopathic).
GHD may be caused by a tumor in the brain. These tumors are normally located at the site of the pituitary gland or the nearby hypothalamus region of the brain. In children and adults, serious head injuries, infections, and radiation treatments can also cause GHD, which is known as acquired GHD (AGHD). However, in rare cases, GHD can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally, in many cases, the cause of GHD is not known or idiopathic.
Children have increased risk of GHD in case of occurrence of a brain injury, brain tumor and/or radiation treatment to the head. The signs and symptoms of children with GHD include short stature, round faces, chubby or “baby fat” around the abdomen, even though the rest of the body proportions are normal. However, if GHD develops later in a child’s life, such as from a brain injury or tumor, its main symptom is delayed puberty. In some instances, sexual development is halted as well.
Some of the Growth hormone deficiency Companies are:
·         Ascendis Pharma
·         Pfizer
·         Opko
·         Merck & Genentech
·         Lumos Pharma
·         Genexine
·         And Many Others
View Report: https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
 Chronic Pruritus Market
DelveInsight's "Chronic Pruritus Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Pruritus, historical and forecasted epidemiology as well as the Chronic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pruritus or itching is an unpleasant feeling that causes a desire to scratch, which negatively affects psychological and physical aspects of the life. It is the most common symptom of skin diseases, sometimes trifling or light and sometimes intolerable.
Some of Chronic Pruritus Companies are:
·         Cara Therapeutics
·         Ulorac
·         UCB Pharma
·         Sanofi Aventis
·         Pfizer
·         Actavis Plc
·         And Many Others
View Report: https://www.delveinsight.com/report-store/chronic-pruritus-market
 Giant Papillary Conjunctivitis Market
DelveInsight's "Giant Papillary Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Giant Papillary Conjunctivitis, historical and forecasted epidemiology as well as the Giant Papillary Conjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Scope of the Giant Papillary Conjunctivitis Report
The report covers the     descriptive overview of Giant Papillary Conjunctivitis, explaining its     causes, signs and symptoms, pathophysiology, diagnosis and currently     available therapies
Comprehensive insight has been     provided into the Giant Papillary Conjunctivitis epidemiology and     treatment in the 7MM
Additionally, an all-inclusive     account of both the current and emerging therapies for Giant Papillary     Conjunctivitis are provided, along with the assessment of new therapies,     which will have an impact on the current treatment landscape
A detailed review of Giant     Papillary Conjunctivitis market; historical and forecasted is included in     the report, covering drug outreach in the 7MM
The report provides an edge     while developing business strategies, by understanding trends shaping and     driving the global Giant Papillary Conjunctivitis market
View Report: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
0 notes
delveinsightme · 29 days ago
Text
ASCO Abstracts 2020 | axi cel, gsk3359609, atezo bev hcc, keynote 204, ino 5401
 ASCO: axi-cel in ZUMA-1
Abstract No : 8012
Abstract Type : Oral Abstract Session
Indication : Diffused Large B-Cell Lymphoma (DLBCL)
Intervention : Yescarta
Company : Kite, a Gilead Company
Technology : CAR T Cell Therapy
Based on this limited sample size, reTx with axi-cel may have clinical efficacy, although transient, in some pts, especially those who achieve CR with 1st Tx. CAR T cell expansion and severe CRS and NEs may be attenuated at reTx. Further studies with additional pts are needed to confirm these results.
View More: https://www.delveinsight.com/asco-conference/article/zuma-1
 GSK: Cell Therapy and Next-generation Immuno-oncology
At this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.
View More: https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology
 IMbrave150 TRIAL of Atezolizumab
Atezo + Bev HCC
IMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy. Pts achieved CRs regardless of poor prognostic factors or etiology. Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.
View More: https://www.delveinsight.com/asco-conference/article/imbrave150
 ASCO: KEYNOTE-204
Abstract No : 8005
Abstract Type : Oral Abstract Session
Indication : Hodgkin’s Lymphoma (HL)
Intervention : Pembrolizumab
Company : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
Technology : Immunocheckpoint
In pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports. Pembro monotherapy should be standard of care for this pt population with R/R/cHL.
View More: https://www.delveinsight.com/asco-conference/article/NCT02684292
 ASCO: INO-5401 + INO-9012 with Cemiplimab
Abstract No : 2514
Abstract Type : Oral Abstract Session
Indication : Glioblastoma Multiforme
Intervention : INO-5401 and INO-9012 + Cemiplimab
Company : Inovio Pharma
Technology : T cell therapy/Monoclonal Antibody
INO-5401 + INO-9012 in combination with cemiplimab and RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival advantage in patients with newly-diagnosed GBM.
View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683
0 notes
delveinsightme · a month ago
Text
Pharmaceutical Consulting
Pharmaceutical Consulting Companies invest considerably in product development, pre- and post-launch product launches, and other activities like mergers, buyouts, and acquisitions. This is in one necessary for increasing growth curve and exponential profit yield.
However, three major types of risks, namely Scientific risks, Economic risks, and Delivery risks, are always looming above them. Development, manufacturing of product through various clinical phases, and transitions from phase to another usually takes an average of 10 years. Even after that, the road is not free from obstacles. The failure of the drug at the last stage, as has been observed in many cases.
Then, the pressure of ensuring the affordability of the therapies to patients awaits after the commercialization of the product. In addition to this, market competition, expiring patents, slow sales, lower profit margins, cost factor, are other significant challenges that come across pharma companies and need to be addressed with their strategized, optimized go-to-market strategy.
It is imperative for them to have a significant focus on innovation and R&D to address unmet needs and to keep in parallel with healthcare reforms and follow regulatory guidelines. In this continually increasing competition and changing landscape, pharma companies need to reform their market strategies.
Some of the Go-to-market strategies undertaken by Pharmaceutical Consulting UK companies to enable better client experience and foster relations are as follows:
Customer-centric market model
Digitally enabled
Lower operational costs
High Return on investment
Customized solutions
Better infrastructure
Without a doubt, Pharma companies would be only able to communicate well only after they have better understanding of the needs of their clients. Moreover, to facilitate better adherence of medication, and diagnostics tools, it is important to have personalized and customized services.
Innovative technologies such as 3D printing, and block chain technology leverage more opportunities that form a part of pharma’s go-to-market strategy for sustainable growth of the pharma industry.
Overall, way to success is to embed all of these strategies in the launch plan of their go-to-market model after commercialization of the product.
Read More- https://www.delveinsight.com/consulting
Healthcare Business Consulting Solutions:
DelveInsght's Healthcare Consulting service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.
Our Services Include:
1.       Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
2.       Healthcare Licensing Services:
https://www.delveinsight.com/consulting/licensing-services
3.       Healthcare Portfolio Management Services: https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions
4.       Healthcare Asset Prioritization Services:
https://www.delveinsight.com/consulting/asset-prioritizaton-services
5.       Healthcare R and D Analysis:
https://www.delveinsight.com/consulting/r-and-d-analysis
6.       Healthcare Merger and Acquisition:
https://www.delveinsight.com/consulting/merger-and-acquisition
7.       Healthcare Business Development Services: https://www.delveinsight.com/consulting/business-development-services
8.       Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
9.       Healthcare Pipeline Assessment:
https://www.delveinsight.com/consulting/pipeline-assessment-services
10.   Healthcare Market Assessment:
https://www.delveinsight.com/consulting/market-assessment-services
11.   Healthcare Regulatory Analysis:
https://www.delveinsight.com/consulting/regulatory-analysis-services
12.   Healthcare Due Diligence Services:
https://www.delveinsight.com/consulting/due-diligence-services
13.   Healthcare Competitive Intelligence: https://www.delveinsight.com/consulting/competitive-intelligence-services
0 notes
delveinsightme · a month ago
Text
ASCO and ESMO Absctracts
Asco: Follow Up Of Lifileucel Treatment
Abstract No : 10006
Indication : Melanoma
Intervention : lifileucel (LN-144)
Company : Iovance Biotherapeutics, Inc.
Technology : TIL
Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant.
View More: https://www.delveinsight.com/asco-conference/article/lifileucel-LN-144
 ASCO: Pegilodecakin
Abstract No : 9563
Abstract Type : Poster Session
Indication : PD-L1 selected NSCLC
Intervention : Pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P
Company : Eli Lilly and Company
Technology : Monoclonal antibody
Adding PEG to P did not lead to improvement in ORR, PFS, or OS, in 1L advanced NSCLC with high PD-L1 expression. PEG+P arm demonstrated expected safety profile but overall higher toxicity compared to pembrolizumab alone.
View More: https://www.delveinsight.com/asco-conference/article/NCT03382899
 ASCO: Results from DREAMM-2 study
Abstract No : 8536
Abstract Type : Poster Discussion Session
Indication : Multiple Myeloma
Intervention : Belantamab mafodotin
Company : GlaxoSmithKline
Technology : BCMA Inhibitor
Belantamab mafodotin (GSK2857916) sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated RRMM. Being the first in class BCMA targeting ADC gives it a significant advantage over its competitors
View More: https://www.delveinsight.com/asco-conference/article/NCT03525678
 ESMO Abstracts:
 CheckMate 238 Results at ESMO 2020
Abstract No : Abstract: #1076O
Indication : Melanoma
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
NIVO continued to demonstrate improved RFS and DMFS vs IPI at 48 mo in pts with stage III/IV melanoma at high risk of recurrence. OS events (n = 211) were lower than anticipated (n = 302). OS rates were similar to NIVO and IPI, although use of subsequent IO therapy was higher in the IPI arm. Late-emergent TRAEs were consistent with the established safety profile of NIVO and IPI, with more events reported with IPI.
View More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-238-NCT02388906-esmo-2020
 CHRYSALIS study results at ESMO 2020
Abstract No : Abstract 1258O
Indication : Non-small cell lung cancer
Intervention : Amivantamab + lazertinib
Company : CHRYSALIS study
Technology : EGFR-MET bispecific antibody + TKI
Amivantamab (JNJ-61186372) can be combined safely with lazertinib at their respective full monotherapy doses. Encouraging preliminary activity was observed in osimertinib-relapsed disease
View More: https://www.delveinsight.com/esmo-conference-2020/article/chrysalis-study-NCT02609776-esmo-2020
 PALLAS Trial: adjuvant palbociclib with endocrine therapy vs. endocrine therapy alone for HR+/HER2- early breast cancer
Abstract No : Presentation LBA12
Indication : Breast cancer
Intervention : Palbociclib
Company : Pfizer
Technology : CDK4/6 Inhibitor
Within the PALLAS trial, at IA2, two years of adjuvant palbociclib with ET did not improve iDFS compared to ET alone. Ongoing long-term follow-up and additional clinical and translational analyses will explore the effect of P in this patient population.
View More: https://www.delveinsight.com/esmo-conference-2020/article/PALLAS-pfizer-esmo-2020
About Delveinsight
DelveInsight is a leading Business Consultant, and Pharmaceutical Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
0 notes
delveinsightme · a month ago
Text
Acute Lung Injury Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Altor BioScience, Apeiron Biologics, Theravance Biopharma, Viela Bio, ReAlta Life Sciences, Cantex Pharmaceuticals, Asklepion Pharmaceuticals and Others
Acute Lung Injury is a life-threatening condition caused by severe acute hypoxemic respiratory failure. It is a key source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a substantial impact on public health, with a high incidence across the world and it requires administration of a fast and goal-oriented therapy to suppress further lung damage.
DelveInsight's "Acute Lung Injury Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Lung Injury, historical and forecasted epidemiology as well as the Acute Lung Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Facts of Acute Lung Injury Market Report:
·         The rising prevalence of acute lung injuries is expected to boost market growth over the forecast period.
·         For instance, according to the National Heart, Lung, and Blood Institute, 79 people per 100,000 population per year developed acute lung injury (ALI), and 59 of these met the criteria for the more severe form of acute respiratory distress syndrome. The death rate of acute lung injury patients was around 38.5 %.
·         Using the US census and assuming the same frequency throughout the country, 190,600 people per year develop ALI, and 74,500 dies off, or with, the disease in the US. Thus, the rising prevalence of acute lung injuries is driving the market.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
View Report: https://www.delveinsight.com/report-store/acute-lung-injury-market
Some of Acute Lung Injury Companies are:
·         Altor BioScience
·         Apeiron Biologics
·         Theravance Biopharma
·         Viela Bio
·         ReAlta Life Sciences
·         Cantex Pharmaceuticals
·         Asklepion Pharmaceuticals
·         Stemedica Cell Technologies
·         Forschung und Entwicklung
·         FirstString Research
·         Histocell S.L.
·         GlaxoSmithKline
·         S-Evans Biosciences
·         CompleGen
·         Commence Bio
·         Windtree Therapeutics
·         And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
View Report: https://www.delveinsight.com/report-store/acute-lung-injury-market
Scope of Acute Lung Injury Market:
The     report covers the descriptive overview of Acute Lung Injury, explaining     its causes, signs and symptoms, pathophysiology, diagnosis and currently     available therapies
Comprehensive     insight has been provided into the Acute     Lung Injury epidemiology and treatment in the 7MM
Additionally,     an all-inclusive account of both the current and emerging therapies for     Acute Lung Injury are provided, along with the assessment of new therapies,     which will have an impact on the current treatment landscape
A     detailed review of Acute Lung Injury market; historical and forecasted is     included in the report, covering drug outreach in the 7MM
The     report provides an edge while developing business strategies, by     understanding trends shaping and driving the global Acute Lung Injury     market
Some of Acute Lung Injury Therapies are:
·         APN01
·         TD-0903
·         VIB7734
·         RLS 0071
·         Dociparstat sodium
·         L-citrulline
·         And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
View Report: https://www.delveinsight.com/report-store/acute-lung-injury-market
Key Acute Lung Injury Market Questions:
What     was the Acute Lung Injury market share (%) distribution in 2017 and how it     would look like in 2030?
What     would be the Acute Lung Injury total market size as well as market size by     therapies across the 7MM during the forecast period (2017-2030)?
What     are the key findings pertaining to the market across 7MM and which country     will have the largest Acute Lung Injury market size during the forecast     period (2017-2030)?
At     what CAGR, the Acute Lung Injury market is expected to grow in 7MM during the     forecast period (2017-2030)?
What     would be the Acute Lung Injury market outlook across the 7MM during the     forecast period (2017-2030)?
What     would be the Acute Lung Injury market growth till 2030, and what will be     the resultant market Size in the year 2030?
How     would the market drivers, barriers and future opportunities affect the     market dynamics and subsequent analysis of the associated trends?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
View Report: https://www.delveinsight.com/report-store/acute-lung-injury-market
Table of Contents:
1. Key Insights
2. Executive Summary of Acute Lung Injury
3. Competitive Intelligence Analysis for Acute Lung Injury
4. Acute Lung Injury: Market Overview at a Glance
5. Acute Lung Injury: Disease Background and Overview
6. Patient Journey
7. Acute Lung Injury Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Acute Lung Injury Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Acute Lung Injury: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute Lung Injury
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Discuss the evolving trends of market landscape @ Acute Lung Injury Market Forecast
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions
Other Links:
·         Electrophysiology Devices Market
·         Growth Hormone Deficiency Market
·         Interventional Neuroradiology Market
·         Intracranial Pressure Monitoring Devices Market
·         Foot and Ankle Devices Market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact us
 Ankit Nigam
 info@delveinsight.com
 +91-9650213330
 https://www.delveinsight.com/
 Connect With Us at:
 LinkedIn | Facebook | Twitter
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
0 notes
delveinsightme · a month ago
Text
Head and Neck Squamous Cell Carcinoma Market: Industry Analysis, Drugs, Key Companies by DelveInsight
DelveInsight's "Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Head and Neck Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Facts of Head and Neck Squamous Cell Carcinoma Market Report:
·         According to World Health Organization, 2014, the annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year.
·         Male to female ratio ranges from 2:1 to 4:1.
·         About 90% of all head and neck cancers are squamous cell carcinomas (HNSCC).
·         SCC is the most frequent malignant tumor of the head and neck region.
·         HNSCC represents the sixth leading cancer by incidence and there are 500,000 new cases a year worldwide (Kamangar et al., 2006).
·         Expected launch of the pipeline therapies shall fuel the growth of the market during the forecast period, i.e., 2021–2030.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market
View Report:  https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market
Some of Head and Neck Squamous Cell Carcinoma Companies are:
·         Merck
·         Sinocelltech Ltd.
·         GlaxoSmithKline
·         Hoffmann-La Roche
·         Kura Oncology
·         AVEO Pharmaceuticals, Inc.
·         Adlai Nortye
·         And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market
View Report:  https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market
Head and neck cancer is a term used to define cancer that develops in the mouth (oral cavity), throat, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these are classified as squamous cases which cover the 90% of the disease area.
The TNM staging system of the AJCC maintains uniformity in the staging of head and neck tumors which varies with the anatomic location of the primary tumor. Most patients with head and neck cancer have stage III or IV disease at diagnosis and a few patients present with the early stage disease.
The causes of head and neck cancers are not fully understood. There are certain risk factors that increase the risk of developing the disease such as smoking tobacco, consumption of alcohol and exposure to the human papillomavirus (HPV) which contributes to the development of at least 90% of squamous cell carcinoma of the head and neck. At least 12% of pharyngeal cancer, 3% of oral cancer, and 30–60% of oropharyngeal carcinoma cases are caused by HPV infection.
Some of Head and Neck Squamous Cell Carcinoma Therapies are:
·         Lenvatinib (E7080/MK-7902)
·         SCT-I10A+ chemo
·         GSK3359609
·         Atezolizumab
·         Tipifarnib
·         Ficlatuzumab
·         Buparlisib (AN2025)
·         And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market
View Report:  https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market
Scope of Head and Neck Squamous Cell Carcinoma Report:
The     report covers the descriptive overview of Head and Neck Squamous Cell     Carcinoma, explaining its causes, signs and symptoms, pathophysiology,     diagnosis and currently available therapies
Comprehensive     insight has been provided into the Head     and Neck Squamous Cell Carcinoma epidemiology and treatment in     the 7MM
Additionally,     an all-inclusive account of both the current and emerging therapies for     Head and Neck Squamous Cell Carcinoma are provided, along with the     assessment of new therapies, which will have an impact on the current     treatment landscape
A     detailed review of Head and Neck Squamous Cell Carcinoma market;     historical and forecasted is included in the report, covering drug     outreach in the 7MM
The     report provides an edge while developing business strategies, by     understanding trends shaping and driving the global Head     and Neck Squamous Cell Carcinoma market.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market
Table of Contents:
1. Key Insights
2. Executive Summary of Head and Neck Squamous Cell Carcinoma
3. Competitive Intelligence Analysis for Head and Neck Squamous Cell Carcinoma
4. Head and Neck Squamous Cell Carcinoma: Market Overview at a Glance
5. Head and Neck Squamous Cell Carcinoma: Disease Background and Overview
6. Patient Journey
7. Head and Neck Squamous Cell Carcinoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Head and Neck Squamous Cell Carcinoma Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Head and Neck Squamous Cell Carcinoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Head and Neck Squamous Cell Carcinoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions
Other Links:
·         Electrophysiology Devices Market
·         Growth Hormone Deficiency Market
·         Interventional Neuroradiology Market
·         Intracranial Pressure Monitoring Devices Market
·         Foot and Ankle Devices Market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact us
 Ankit Nigam
 info@delveinsight.com
 +91-9650213330
 https://www.delveinsight.com/
 Connect With Us at:
 LinkedIn | Facebook | Twitter
Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market
0 notes
delveinsightme · a month ago
Text
Growth Hormone Deficiency Market
Growth hormone deficiency is a condition where the pituitary gland is unable to make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A third category has no known or diagnosable cause (idiopathic). Growth hormone deficiency may be caused by a tumor in the brain. These tumors are normally located at the site of the pituitary gland or the nearby hypothalamus region of the brain. In children and adults, serious head injuries, infections, and radiation treatments can also cause Growth hormone deficiency, which is known as acquired Growth hormone deficiency (AGHD). However, in rare cases, Growth hormone deficiency can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally, in many cases, the cause of Growth hormone deficiency is not known or idiopathic.
DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Growth hormone deficiency Market Report Facts are:
·         As per the study by Bonfig et al. (2019) titled “Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes,” the prevalence of GHD ranges between 1/3500 and 1/8700 in Germany.
·         According to the Boston Children’s Hospital, about 1 in 4,000–10,000 children have GHD.
·         Several secondary sources suggest that GHD is slightly more prevalent in males than in females.
·         According to the Growth Hormone Foundation estimates, more than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year, including GHD children who transition to GHD as an adult.
·         It is estimated that in the adult UK population at any given time, approximately 1 in every 10,000 people will have adult-onset GHD, which works out to approximately 12,600 adults with GHD in England and Wales.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market
Some of Growth hormone deficiency Companies are:
·         Ascendis Pharma
·         Pfizer
·         Opko
·         Lumos Pharma
·         Novo Nordisk
·         Ipsen
·         Pfizer
·         And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market
Scope of the Growth hormone deficiency Report:
The     report covers the descriptive overview of Growth Hormone Deficiency,     explaining its causes, signs and symptoms, pathophysiology, diagnosis and     currently available therapies
Comprehensive     insight has been provided into the Growth Hormone Deficiency epidemiology     and treatment in the 7MM
Additionally,     an all-inclusive account of both the current and emerging therapies for     Growth Hormone Deficiency are provided, along with the assessment of new     therapies, which will have an impact on the current treatment landscape
A     detailed review of Growth Hormone Deficiency market; historical and     forecasted is included in the report, covering drug outreach in the 7MM
The     report provides an edge while developing business strategies, by     understanding trends shaping and driving the global Growth Hormone     Deficiency market
Some of Growth hormone deficiency therapies are:
·         TransCon hGH
·         Somatrogon
·         LUM-201
·         Norditropin
·         Sogroya (somapacitan)
·         Increlex
·         Genotropin
·         And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market
Table of Contents:
1. Key Insights
2. Executive Summary of Growth Hormone Deficiency
3. Competitive Intelligence Analysis for Growth Hormone Deficiency
4. Growth Hormone Deficiency: Market Overview at a Glance
5. Growth Hormone Deficiency: Disease Background and Overview
6. Patient Journey
7. Growth Hormone Deficiency Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Growth Hormone Deficiency Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Growth Hormone Deficiency: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Growth Hormone Deficiency
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market
Other Links:
·         Electrophysiology Devices Market
·         Growth Hormone Deficiency Market
·         Interventional Neuroradiology Market
·         Intracranial Pressure Monitoring Devices Market
·         Foot and Ankle Devices Market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact us Ankit Nigam info@delveinsight.com +91-9650213330 https://www.delveinsight.com/ Connect With Us at: LinkedIn | Facebook | Twitter
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market
0 notes
delveinsightme · a month ago
Text
DelveInsight has launched New Medical Device Reports: Electrophysiology Devices Market, Interventional Neuroradiology Market, Intracranial Pressure Monitoring Devices Market, Foot and Ankle Devices Market
Electrophysiology Devices Market
DelveInsight’s ‘Electrophysiology Devices Market Insights, Competitive Landscape and Market Forecast - 2026’ report delivers an in-depth understanding of Electrophysiology Devices and the historical and forecasted Electrophysiology Devices market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
List of Electrophysiology Devices Companies:
Boston     Scientific Corporation
Medtronic     Plc.
Abbot     Laboratories
Biosense     Webster, Inc. (Johnson & Johnson)
Biotronik     SE & Co. KG
GE     Healthcare
Siemens     Healthcare
View Report: https://www.delveinsight.com/report-store/electrophysiology-devices-market
 Interventional Neuroradiology Market
DelveInsight’s ‘Interventional Neuroradiology Market Insights, Competitive Landscape and Market Forecast - 2026’ report delivers an in-depth understanding of Interventional Neuroradiology and the historical and forecasted Interventional Neuroradiology market trends in the US, EU5 (Germany, France, Spain, Italy, and United Kingdom) and Japan.
List of Interventional Neuroradiology Companies:
Abbott
B.     Braun Melsungen AG
Boston     Scientific Corporation
Medtronic     PLC
Stryker     Corporation
Johnson     & Johnson
Terumo     Corporation
Penumbra,     Inc.
Merit     Medical Systems, Inc.
MicroPort     Scientific Corporation
W.     L. Gore & Associates, Inc.
Cook     Medical.
View Report: https://www.delveinsight.com/report-store/interventional-neuroradiology-market
 Intracranial Pressure Monitoring Devices Market
DelveInsight’s ‘Intracranial Pressure Monitoring Devices Market Insights, Competitive Landscape and Market Forecast–2026’ report delivers an in-depth understanding of Intracranial Pressure Monitoring Devices and the historical and forecasted Intracranial Pressure Monitoring Devices market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.
List of Intracranial Pressure Monitoring Devices Companies:
Medtronic     plc;
Integra     LifeSciences Holdings Corporation;
Codman     & Shurtleff, Inc.,
RAUMEDIC     AG;
Vittamed;
Orsan     Medical Technologies;
and     Spiegelberg GmbH & Co. KG.,
Sophysa     SA,
Vivonics     Inc.,
Neural     Analytics,
Natus     Medical Incorporated
View Report: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
 Foot and Ankle Devices Market
DelveInsight’s ‘Foot and Ankle Devices Market Insights, Competitive Landscape and Market Forecast - 2025’ report delivers an in-depth understanding of Foot and Ankle Devices and the historical and forecasted Foot and Ankle Devices market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
List of Foot and Ankle Devices Companies:
·         Integra Life Sciences
·         Implants International
·         Small Bone Innovation, Inc.
·         DePuy Synthes
·         Zimmer Holdings, Inc.
·         KYOCERA Medical Corporation
View Report: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
0 notes
delveinsightme · 2 months ago
Text
Market and Competitive Opportunity Solution help a Medical Device Company Assess the Landscape of Cell Imaging Technology domain| Identification of Top Competitors through Competitive Intelligence | DelveInsight
(Albany, US) Traditional method of toxicity and drug safety studies is expensive, has a low success rate, and is resource- and time-consuming. To overcome these challenges, pharmaceutical companies are increasingly adopting high-content screening (HCS) cell-based assays for identifying the effects of toxicity in drug development studies (cell-based imaging enables the monitoring of drug toxicity mechanisms, such as oxidative stress, micronuclei, mitochondrial dysfunction, steatosis, and apoptosis).
DelveInsight is the world's leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed to connect your organization’s goals with global opportunities. RFP to know more about DelveInsight’s competitive intelligence for pharma companies.
Market & Competitive Assessment
Business Problem:
A large Asian conglomerate was working to develop their asset portfolio in Cell Imaging and Analysis, and was interested to assess the market scenario of software based devices in the Cell Analysis and Cell Observation segment, such as HCS, Cell Analyzers, Flow Cytometers etc., to understand the past and forecasted market, to assess decision of possible market entry and potential future commercial success. The client requested evidence-based market estimation, segmented by type, end users, and application in US, EU, and some select APAC nations.
Download Case Study: https://www.delveinsight.com/case-study/market-&-competitive-assessment
Want comprehensive insights into the market drivers, challenges, key industry players, and more in the pharma neonatal MSCs Opportunity Assessment? Request a free proposal
Our Approach
Understanding Competition in the market, assess product portfolios and geographical reach to assess the landscape.
Evaluating historical country- and company- based revenue and assessing relevant market segmentation.
Deep-dive assessments into the device price and overall Market Size Assessment and Forecast and Outcome reporting.
DelveInsight is well versed in a multitude of qualitative and quantitative solutions to address your competitive intelligence needs. Learn more about our services portfolio for pharmaceutical companies. Request for more information.
Results:
·         Led to changes in KPI targeting through understanding region-centric market differences
·         Helped assess points of improvement in sales plan through understanding user perspectives
·         Improved resource allocation for achieving higher sales target
Learn more about our services portfolio for pharmaceutical companies. Request for more information.
DelveInsight's Consulting Services include but not restricted to the following:
Competitive Intelligence Services: CI Services that are centered on DelveInsight's competitive model, help clients identify tenable market threats and strategize to yield maximum ROI. 
View Here: https://www.delveinsight.com/consulting/competitive-intelligence-services
Licensing Services: Providing customized solutions to help clients manage assets and strategize developmental needs for maximum output through DelveInsight's licensing services.
View Here: https://www.delveinsight.com/consulting/licensing-services
Portfolio Management Services: By assessing trends, analyzing returns and gathering insight on best opportunities, DelveInsight provides high-value guidance for managing clients' portfolio.
View Here: https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions
Mergers and Acquisitions: Identify emerging markets trends and gain insight on untapped opportunities to expand and grow in the market with DelveInsight.
View Here: https://www.delveinsight.com/consulting/merger-and-acquisition
Healthcare Due Diligence: DelveInsight identifies financial risks, profits, and synergies and help clients make sound business decisions. 
View Here: https://www.delveinsight.com/consulting/due-diligence-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.
Solutions     from the Pre-clinical phase till commercialisation
Expand     your business to different geographies round the world
Unfold     a 360° panoramic view of the market
 To know more, visit:  https://www.delveinsight.com/consulting
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact us Ankit Nigam info@delveinsight.com +91-9650213330 https://www.delveinsight.com/ Connect With Us at: LinkedIn | Facebook | Twitter
0 notes
delveinsightme · 2 months ago
Text
ESMO and ASCO Abstracts 2020
Tumblr media
ESMO Abstracts:
CheckMate 067 Results at ESMO 2020
Abstract No : Abstract: #1105P
Indication : Melanoma
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
Mixture models adequately captured the survival plateaus in CheckMate 067 and suggested a higher proportion of LTSs with NIVO and NIVO+IPI than with IPI. These methods may be used in the indirect estimation of auxiliary outcomes, such as time to subsequent treatment and impact of subsequent treatments on LTSs.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-067-NCT01844505-esmo-2020
 CheckMate -577 Results at ESMO 2020
Abstract No : Abstract: #LBA9
Indication : Esophageal Cancer, Gastroesophageal junction cancer
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
Adjuvant nivolumab is the first therapeutic to provide a statistically significant and clinically meaningful improvement in DFS vs placebo and a well-tolerated safety profile in patients with resected EC/GEJC, who have received neoadjuvant CRT. These results represent the first treatment advance in many years for these patients, potentially establishing adjuvant nivolumab as a new standard of care.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-577-esmo-2020
 KEYNOTE-590 Results at ESMO 2020
Abstract No : Abstract #LBA8
Indication : Esophageal cancer
Intervention : Pembrolizumab
Company : Merck & Co.
Technology : PD-1/PD-L1 inhibitor
Pembro + chemo provided superior OS, PFS, and ORR vs chemo, with a manageable safety profile in pts with untreated, advanced esophageal and EGJ cancer. These data demonstrate that 1L pembro + chemo is a new standard of care in this pt population.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-590-NCT03189719-esmo-2020
Tumblr media
ASCO Abstracts:
ASCO: Results of KEYNOTE-426
Abstract No : 5001
Abstract Type : Oral Abstract Session
Indication : Renal Cell Carcinoma
Intervention : Pembrolizumab + axitinib
Company : Merck & Co.
Technology : Immune Checkpoint Inhibitor (ICI)
Pembro + axi continued to demonstrate superior and durable antitumor activity vs sunitinib in pts with first-line aRCC with a 27-mo median follow up; no new safety signals were observed.
Read More: https://www.delveinsight.com/asco-conference/article/NCT02853331
0 notes
delveinsightme · 2 months ago
Text
ASCO and ESMO Abstracts
ASCO Abstracts 2020
ASCO: Results of IMpower110 study
Abstract No : 9594
Abstract Type : Poster Session
Indication : Non-Small Cell Lung Cancer
Intervention : Atezolizumab (atezo) vs chemotherapy
Company : F. Hoffmann-La Roche, Ltd
Technology : Monoclonal antibody
QLQ-C30 and QLQ-LC13 completion rates were high at BL and most study visits. TTD of lung cancer-related symptoms was similar in both arms, indicating pts’ low BL symptom burden was maintained for a similar duration. Pts receiving atezo vs chemo sustained numerical improvements in physical function and no worsening in lung cancer-related symptoms.
Read More: https://www.delveinsight.com/asco-conference/article/NCT02409342
 ASCO: Results from CARTITUDE-1
Abstract No : 8505
Abstract Type : Oral Abstract Session
Indication : Multiple Myeloma
Intervention : JNJ-4528
Company : Janssen Research & Development, LLC
Technology : CAR T Cell Therapy
JNJ-4528 treatment led to responses in all pts. These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up. CRS was manageable in most pts, supporting outpatient dosing.
View More: https://www.delveinsight.com/asco-conference/article/NCT03548207
 ASCO: Results of IMvigor130
Abstract No : 5011
Abstract Type : Clinical science symposium
Indication : Urothelial Carcinoma
Intervention : Atezolizumab
Company : Roche
Technology : Monoclonal antibody
These results reinforce the potential predictive nature of biomarkers associated with response/resistance to atezo and highlight potentially distinct biology driving benefit with atezo and atezo + PBC. These findings suggest a possible biomarker-directed approach to 1L mUC tx that warrants mechanistic interrogation and prospective validation.
Read More: https://www.delveinsight.com/asco-conference/article/imvigor130
 ESMO Conference 2020:
 CheckMate-649 Results at ESMO 2020
Abstract No : Abstract: #LBA6
Indication : Gastric Cancer, Gastroesophageal junction cancer and Esophageal Cancer
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
CheckMate-649
NIVO is the first PD-1 inhibitor to demonstrate superior OS and PFS in combination with chemo vs chemo alone in previously untreated pts with advanced GC/GEJC/EAC, with a manageable safety profile. NIVO + chemo represents a potential newstandard 1L treatment option for these pts.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-649-NCT02872116-esmo-2020
 ADAURA trial results at ESMO
ADAURA is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC resulting in the complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
View More: https://www.delveinsight.com/esmo-conference-2020/article/ADAURA-trial-results-presented-at-esmo-2020
 Keynote -361 Trial:  Fails to Meet Primary Endpoints
“Danube phase III with dual checkpoint blockade versus standard chemo fails to improve outcomes. Keynote 361 IO vs. Chemo also negative. Perhaps Javelin 100 is positive because it's already selected patients who responded to chemo for the use of maintenance IO”
Read More: https://www.delveinsight.com/esmo-conference-2020/article/urothelial-carcinoma-esmo-2020
0 notes
delveinsightme · 2 months ago
Text
DelveInsight has launched new reports: Bile Duct Neoplasm Market, Dermatomycoses Market, Familial Primary Pulmonary Hypertension Market and Intravenous Immunoglobulin Market
Tumblr media
Bile Duct Neoplasm Market
DelveInsight's "Bile Duct Neoplasms Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bile Duct Neoplasms , historical and forecasted epidemiology as well as the Bile Duct Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Bile Duct Neoplasm Companies:
·         Agios Pharmaceuticals
·         AstraZeneca
·         Merck/EMD Serono
·         QED Therapeutics
·         Nucana
·         Lexicon Pharmaceutical
·         And Many Others
View Report: https://www.delveinsight.com/report-store/bile-duct-neoplasms-market
 Dermatomycoses Market
DelveInsight's "Dermatomycoses Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Dermatomycoses , historical and forecasted epidemiology as well as the Dermatomycoses market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dermatomycoses Companies:
·         Anacor Pharmaceuticals Inc
·         Biolab Farmaceutica Ltda
·         Blueberry Therapeutics Ltd
·         Daewoong Pharmaceutical Co Ltd
·         Dermala Inc
·         Helix BioMedix Inc
·         Novan Inc
·         Sol-Gel Technologies Ltd
·         TGV-Laboratories
·         Viamet Pharmaceuticals Inc
·         Vyome Biosciences Pvt Ltd
View Report: https://www.delveinsight.com/report-store/dermatomycoses-market
 Familial Primary Pulmonary Hypertension Market            
DelveInsight's "Familial Primary Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Familial Primary Pulmonary Hypertension , historical and forecasted epidemiology as well as the Familial Primary Pulmonary Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Familial primary pulmonary hypertension is a rare autosomal dominant disorder that has reduced penetrance and that has been mapped to a 3-cM region on chromosome 2q33 (locus PPH1). The phenotype is characterized by monoclonal plexiform lesions of proliferating endothelial cells in pulmonary arterioles. These lesions lead to elevated pulmonary-artery pressures, right-ventricular failure, and death. Although primary pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs, including phentermine-fenfluramine.
View Report: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
 Intravenous Immunoglobulin Market            
Intravenous immunoglobulin (also referred to as IVIG) is a product made up of antibodies that can be given intravenously. According to the American College of Rheumatology, it is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors.
Immunoglobulins are made by the immune system of healthy people to fight infections. While IVIG is derived from plasma (a blood product), it is so purified that the chances of contracting a blood-borne infection are extremely low.
Traditionally, IVIG has been used as replacement therapy for patients with primary or secondary immunoglobulin deficiencies.
However, increasingly, IVIG is being used (in doses higher than for replacement therapy) in certain bacterial or viral infectious diseases as well. A variety of modes of action have been attributed to the beneficial effects of IVIG, including its interaction with T-cell function, antigen-presenting cell maturation/presentation, combined with a general “tune down” effect on inflammatory reactions.
Intravenous Immunoglobulin Companies:
·         Evolve Biologics
·         Biotest
·         Momenta Pharmaceuticals
·         Green Cross Pharma
·         And Many Others
View Report: https://www.delveinsight.com/report-store/intravenous-immunoglobulin-market
0 notes
delveinsightme · 2 months ago
Text
DelveInsight has launched new reports: Post-Surgical Pain Market, Idiopathic Membranous Nephropathy Market, Post Menopausal Osteoporosis Market, Atrial Flutter Market and  Xerostomia Market
Post-Surgical Pain Market      
The Post-Surgical Pain market report provides current treatment practices, emerging drugs, Post-Surgical Pain market share of the individual therapies, current and forecasted Post-Surgical Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Post-Surgical Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Post-Surgical Pain Drugs covered
1. Olinvo (Oliceridine injection or TRV130)
2. HTX011
3. CR845/Difelikefalin
4. NTM001
5. PF05089771
And many others
The key players in Post-Surgical Pain market are:
1. Trevena
2. Heron Therapeutics
3. Cara Therapeutics
4. Neumentum Pharmaceuticals
5. Pfizer
And many others
View Report: https://www.delveinsight.com/report-store/post-surgical-pain-market
 Idiopathic Membranous Nephropathy Market
The Idiopathic Membranous Nephropathy market report provides current treatment practices, emerging drugs, Idiopathic Membranous Nephropathy market share of the individual therapies, current and forecasted Idiopathic Membranous Nephropathy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Idiopathic Membranous Nephropathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Idiopathic Membranous Nephropathy Drugs covered
1. Olinvo (Oliceridine injection or TRV130)
2. HTX011
3. CR845/Difelikefalin
4. NTM001
5. PF05089771
And many others
The key players in Idiopathic Membranous Nephropathy market are:
1. Trevena
2. Heron Therapeutics
3. Cara Therapeutics
4. Neumentum Pharmaceuticals
5. Pfizer
And many others
View Report: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-market
 Post Menopausal Osteoporosis Market        
The Post Menopausal Osteoporosis market report provides current treatment practices, emerging drugs, Post Menopausal Osteoporosis market share of the individual therapies, current and forecasted Post Menopausal Osteoporosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Post Menopausal Osteoporosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
The key players in Post Menopausal Osteoporosis market are:
1. Trevena
2. Heron Therapeutics
3. Cara Therapeutics
4. Neumentum Pharmaceuticals
5. Pfizer
And many others
View Report: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-market
 Atrial Flutter Market: Trends and Opportunities
Increase in the number of people with various common diseases like obesity and diabetes are anticipated to fuel the world market for atrial flutter over the period of forecast. Rise in the prevalence of many different types of heart diseases like stroke, heart attack, and congestive heart failure are also anticipated to propel the said market. In accordance with the World Health Organization, cardiovascular diseases have been the leading cause of death across the globe. More people die every year from cardiovascular diseases than from any other type of disease. Cardiovascular diseases have been responsible for around 17.7 million deaths in the year 2015, thereby representing around 31% of the total deaths across the globe. Out of all of these deaths, around 7.4 million were owing to coronary heart disease and 6.7 million owing to stroke.
View Report: https://www.delveinsight.com/report-store/atrial-flutter-market
 Xerostomia Market        
Xerostomia is defined as the “complaint of oral dryness”. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as “true” xerostomia; however, most patients with xerostomia often do not have objective signs of hypo salivation. “Symptomatic” xerostomia or “pseudo” xerostomia refers to oral dryness despite normal salivary gland function.
Patients with xerostomia can have clinical manifestations of difficulty in swallowing, chewing, and/orspeaking and can present with burning mouth, halitosis, altered taste, dry buccal mucosa, glossitis, cracked and peeled lips, oral candidiasis, and dental caries despite good oral hygiene.
The causes of xerostomia may be divided into two broad categories: systemic diseases and local factors.
Systemic diseases that can cause xerostomia include, but are not limited to, endocrine, autoimmune, infectious, and granulomatous diseases. The more common systemic diseases are reviewed here. Local factors that can cause xerostomia include medications, head and neck radiation therapy, and lifestyle factors.
Xerostomia occurs in 5.5% to 46% of the population, and most commonly in older adults.
View Report: https://www.delveinsight.com/report-store/xerostomia-market
0 notes
delveinsightme · 2 months ago
Text
ASCO and ESMO Abstracts 2020
Tumblr media
ASCO Abstracts
ASCO: Lisocabtagene maraleucel (liso-cel)
Abstract No : 8040
Indication : Non-Hodgkin's Lymphoma (aggressive)
Intervention : Lisocabtagene maraleucel
Company : Juno Therapeutics, a Bristol-Myers Squibb company
Technology : CAR T Cell therapy
These interim data suggest that elderly and/or comorbid pts with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso-cel with similar safety and efficacy to 3L+ pts as previously reported (Abramson, ASH 2019 #241). Updated data with longer follow-up will be presented.
Read More: https://www.delveinsight.com/asco-conference/article/lisocabtagene-maraleucel
 ESMO Abstracts
ADAURA trial results at ESMO
ADAURA is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC resulting in the complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/ADAURA-trial-results-presented-at-esmo-2020
 Renal Cell Carcinoma Highlights- ESMO 2020
The much-awaited late-breaking results of Phase III Checkmate 9ER came out with outstanding outcomes in metastatic 1st line RCC; it evaluated the combination of Cabozantinib/Nivolumab vs. Sunitinib. These impressive results in 651 patients declared that the median PFS has been doubled when compared to Sunitinib, which is 16.6 vs. 8.3m, respectively. The result also evaluated the OS (40% decrease risk of death) & ORR (55.7 vs. 27.1%), with manageable toxicity, efficacy, and tolerability profile with a low rate of treatment-related discontinuations. It was great to hear that the study met both its primary PFS and secondary OS/ORR, demonstrating the superiority of first-line Cabozantinib/Nivolumab vs Sunitinib across key baseline characteristics, including IMDC risk status, tumor PD-L1 expression, and bone metastases.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-9er-renal-cell-carcinoma-highlights-esmo-2020
 KEYNOTE 048 Results at ESMO 2020
Abstract No : Abstract #915MO
Indication : Head & Neck Cancer
Intervention : Pembrolizumab + Chemotherapy
Company : Merck & Co.
Technology : PD-1 inhibitor + Chemo
Long-term follow-up confirmed the statistically significant improvement in OS established at the protocol-specified interim and final analyses for pembro vs E in pts with PD-L1 CPS ≥20 and CPS ≥1 and for pembro+C vs E in pts with PD-L1 CPS ≥20 and CPS ≥1, and total pop. Safety was favorable for pembro vs E and comparable for pembro+C vs E
Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-048-NCT02358031-esmo-2020
 KEYNOTE-177 approves pembrolizumab as SoC and an obvious choice for 1L patients MSI-H/dMMR mCRC
Abstract No : Abstract #396O
Indication : Colorectal Cancer
Intervention : Pembrolizumab
Company : Merck & Co.
Technology : Immune Checkpoint Inhibitor (ICI)
Pembro monotherapy demonstrated clinically meaningful improvements in HRQoL vs SOC chemotherapy in pts with previously untreated MSI-H/dMMR mCRC.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-177-colorectal-cancer
0 notes
delveinsightme · 2 months ago
Text
DelveInsight launches New Pharmaceutical Reports
Hypoparathyroidism Market            
DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hypoparathyroidism , historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hypoparathyroidism is an uncommon condition in which your body produces abnormally low levels of parathyroid hormone (PTH). PTH is key to regulating and maintaining a balance of two minerals in your body — calcium and phosphorus.
Hypoparathyroidism Market Players
Shire-NPS Pharmaceuticals,     Inc., 
F. Hoffmann-La Roche     Ltd, 
Sun Pharmaceutical     Industries Ltd., 
AbbVie Inc., 
Teva Pharmaceutical     Industries Ltd., 
EnteraBio Ltd
And Many Others
Read More: https://www.delveinsight.com/report-store/hypoparathyroidism-market
 Lymphocytopenia Market
DelveInsight's "Lymphocytopenia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Lymphocytopenia, historical and forecasted epidemiology as well as the Lymphocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lymphocytopenia is the condition of having an abnormally low level of lymphocytes in the blood. Lymphocytes are a white blood cell with important functions in the immune system. It is also called lymphopenia. The opposite is lymphocytosis, which refers to an excessive level of lymphocytes.
Lymphocytopenia Market Players
·         NeoImmuneTech
·         RevImmune
·         And Many Others
Read More: https://www.delveinsight.com/report-store/lymphocytopenia-market
 Amyloidosis Market
DelveInsight's "Amyloidosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Amyloidosis , historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Amyloidosis is when an abnormal protein called amyloid builds up in your tissues and organs. When it does, it affects their shape and how they work. Amyloidosis is a serious health problem that can lead to life-threatening organ failure.
Amyloidosis Market Players
·         Pfizer Inc.
·         Alnylam Pharmaceuticals, Inc.
·         Celgene Corporation
·         Millennium Pharmaceuticals, Inc.
·         Onyx Pharmaceuticals, Inc.
·         GlaxoSmithKline Plc
·         And Many Others
Read More: https://www.delveinsight.com/report-store/amyloidosis-market
 Other Links:
·         Anovulation Market
·         Bronchial Spasm Market
·         Centronuclear Myopathy Market
·         Chronic myelogenous leukemia (CML) Market
·         Chronic Refractory Cough (CRC) Market
·         Epithelioid Sarcoma Market
·         Fibrocystic breast condition Market
·         Hypoparathyroidism Market
·         Lymphocytopenia Market
·         Amyloidosis Market
·         Bunion Market
·         Intrahepatic Cholangiocarcinoma (ICC) Market
·         Alcoholic Hepatitis Market
·         wAIHA Market
·         Biliary Tract Cancer (BTC) Market
·         Hepatitis C Market
·         Idiopathic Pulmonary Fibrosis (IPF) Market
·         CIPN Market­­­
0 notes
delveinsightme · 2 months ago
Text
ASCO and ESMO Abstracts 2020
ASCO: Bintrafusp Alfa presented by Merck
Abstract No : 9558
Abstract Type : Poster Session
Indication : Non-Small Cell Lung Cancer
Intervention : Bintrafusp alfa (M7824)
Company : Merck KGaA, Darmstadt, Germany, Pharmaceutical/Biotech Company
Technology : Bifunctional fusion protein
After two years of follow-up, bintrafusp alfa continues to show manageable safety with durable responses and encouraging long-term survival, especially in patients with high PD-L1 expression. A study evaluating bintrafusp alfa vs pembrolizumab as first-line treatment for NSCLC is ongoing in patients with high PD-L1 expression (NCT03631706).
Read More: https://www.delveinsight.com/asco-conference/article/NCT02517398
 ASCO: Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions
Abstract No : 9580
Abstract Type : Poster Session
Indication : NSCLC with EGFR exon 20 insertions
Intervention : TAK-788
Company : Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Technology : Small molecule
Despite a more heavily pretreated pt population, the efficacy of TAK-788 in pts with refractory NSCLC with EGFR exon 20 insertions appears better than other second-line treatment options used in the real-world setting.
Read More: https://www.delveinsight.com/asco-conference/article/NCT02716116
 Adjuvant Therapy For High-risk Her2-positive Early Breast Cancer
Abstract No : 500
Indication : Her2 Positive Breast Cancer
Intervention : trastuzumab emtansine (T-DM1) + pertuzumab
Company : Roche
Technology : Monoclonal antibody
Replacing adjuvant taxane and trastuzumab with T-DM1 did not result in significantly improved efficacy or overall safety. Nonetheless, in this high-risk population, a favorable IDFS outcome was achieved in both study arms. HP + chemotherapy remains the standard of care for patients with high-risk HER2-positive EBC.
Read More: https://www.delveinsight.com/asco-conference/article/trastuzumab-emtansine-pertuzumab
 ESMO: Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated ccRCC
Abstract No : Abstract #LBA26
Indication : Renal cell carcinoma
Intervention : MK 6482 + cabozantinib
Company : Merck & Co.
Technology : PD-1/MultiTKI Inhibitor
MK6482 continued to demonstrate promising antitumor activity against VHL-associated RCC and non-RCC tumors and was well tolerated
Read More: https://www.delveinsight.com/esmo-conference-2020/article/NCT03401788-esmo-2020
0 notes
delveinsightme · 2 months ago
Text
DelveInsight launches new Pharmaceutical Market Research Reports
Chronic myelogenous leukemia Market
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood.
The major players covered in Chronic Myelogenous Leukemia Treatment are:
Bristol-Myers     Squibb
Teva     Pharmaceuticals
Novartis
Bio-Path     Holdings
Pfizer
Incyte
Roche
And     Many Others
View Report: https://www.delveinsight.com/report-store/chronic-myelogenous-leukemia-market
 Hepatitis C Market                        
DelveInsight's "Hepatitis C Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hepatitis C, historical and forecasted epidemiology as well as the Hepatitis C market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV): the virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C is a major cause of liver cancer.
The major players covered in Hepatitis C Treatment are:
·         AbbVie
·         Gilead
·         Kenilworth
·         Merck
·         Johnson & Johnson
·         Bristol-Myers Squibb
·         And Many Others            
View Report: https://www.delveinsight.com/report-store/hepatitis-c-market
 Idiopathic Pulmonary Fibrosis Market
DelveInsight’s ‘Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring (fibrosis) of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen.
The major players covered in Idiopathic Pulmonary Fibrosis Treatment are:
·         FibroGen
·         Kadmon Corporation
·         Promedior
·         Galapagos
·         MediciNova
·         And Many Others
View Report: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market
 Fibrocystic breast condition Market
DelveInsight's "Fibrocystic Breast Condition Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Fibrocystic Breast Condition , historical and forecasted epidemiology as well as the Fibrocystic Breast Condition market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Fibrocystic breast disease, commonly called fibrocystic breasts or fibrocystic change, is a benign (noncancerous) condition in which the breasts feel lumpy. Fibrocystic breasts aren’t harmful or dangerous, but may be bothersome or uncomfortable for some women.
The major players covered in Fibrocystic breast disease Treatment are:
·         Merck & Co.,
·         Pfizer Inc.
·         Teva Pharmaceutical
·         Bayer AG
·         Allergan 
·         And Many Others
View Report: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
0 notes
delveinsightme · 3 months ago
Text
ASCO Abstracts 2020
ASCO Abstracts
 ASCO: Phase III QUAZAR AML-001 trial
 Abstract No : 7530
Abstract Type : Poster Discussion Session
Indication : Acute Myeloid Leukemia
Intervention : CC-486
Company : BMS
Technology : Small molecule
CC-486 is safe and well-tolerated as maintenance therapy in elderly patients ($75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.
 ASCO: KEYNOTE-189 study
 Abstract No : 9582
Abstract Type : Poster Session
Indication : Nonsquamous NSCLC
Intervention : Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro)
Company : Merck Sharp & Dohme Corp.
Technology : Monoclonal antibody
Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC
 ASCO: Initial KarMMa results
 Abstract No : 8503
Abstract Type : Oral Abstract Session
Indication : Multiple Myeloma
Intervention : Idecabtagene vicleucel
Company : Bristol-Myers Squibb and bluebird bio.
Technology : CAR T Cell Therapy
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results
 Anti-cd47 Antibody Magrolimab Combined With Azacitidine
 Abstract No : 7507
Abstract Type : Poster Discussion Session
Indication : MDS/AML
Intervention : Magrolimab
Company : Forty Seven, Inc
Technology : Monoclonal antibody
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results
0 notes
delveinsightme · 3 months ago
Text
Anovulation Market Research Report
DelveInsight's "Anovulation Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Anovulation , historical and forecasted epidemiology as well as the Anovulation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anovulation facts:
· Anovulation may occur in up to 15% of women in their reproductive years.
· During adolescence, transient cystic changes are quite commonly seen during adolescence, and may be mistaken for polycystic ovarian syndrome (PCOS), which is a leading cause of anovulation (over 73%) in young women.
View Report: https://www.delveinsight.com/report-store/anovulation-market
Request for free Sample Copy: https://www.delveinsight.com/sample-request/anovulation-market
Anovulation Symptoms
Women who ovulate regularly often see signs that occur during each cycle. They may experience the following:
increased     amounts of cervical mucus
a     drop and subsequent rise in resting body temperature in the middle of the     menstrual cycle (around day 10-16)
periods     that occur regularly
Women with very irregular periods, or who do not see signs of ovulation, may wish to try an over-the-counter ovulation predictor kit. These kits measure levels of hormones in a woman’s urine to determine when she is ovulating.
A doctor may also be able to test a woman’s hormone levels or carry out an ultrasound scan to view the ovaries.
View Report: https://www.delveinsight.com/report-store/anovulation-market
Request for free Sample Copy: https://www.delveinsight.com/sample-request/anovulation-market
Anovulation Market Outlook
The Anovulation market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Anovulation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a thorough detail of Anovulation market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
View Report: https://www.delveinsight.com/report-store/anovulation-market
0 notes